TSVT - Bristol Myers 2seventy bio to face FDA panel in March for Abecma decision
2024-02-05 07:28:26 ET
More on Bristol-Myers Squibb
- Bristol-Myers Squibb: All Focus On Execution
- Bristol-Myers Squibb: Massive Discount Spells Opportunity
- Bristol-Myers Squibb Company 2023 Q4 - Results - Earnings Call Presentation
- Bristol-Myers Squibb beats in Q4 as Eliquis and Opdivo outperform
- Bristol-Myers Squibb beats top-line and bottom-line estimates; initiates FY24 outlook